![]() |
市場調查報告書
商品編碼
1671216
全球免疫螢光測定市場評估:依產品、類型、應用、最終用戶、地區、機會和預測(2018-2032年)Immunofluorescence Assays Market Assessment, By Products, By Type, By Application, By End-user, By Region, Opportunities and Forecast, 2018-2032F |
全球免疫螢光測定市場規模預計將從2024年的39.3億美元成長到2032年的64.4億美元,在2025-2032年預測期內的年複合成長率為 6.39%。市場成長的動力來自於生技產業的快速擴張、醫療保健產業壓力的加大以及研發活動投資的增加。
此外,免疫螢光檢測在廣泛領域的應用日益廣泛也推動了市場需求。免疫螢光試驗可用於組織和細胞,以確定各種生物化合物(如蛋白質和碳水化合物)的存在或不存在。它也用於分子生物學中來可視化細胞骨架。這些應用大幅支持了全球各地區市場的成長。
自體免疫疾病的威脅日益增加是推動全球免疫螢光檢測市場發展的主要趨勢之一。免疫化學技術可以定位和檢測各種組織類型中的多種抗原,以進行細胞製備。免疫螢光試驗對於診斷自體免疫疾病非常重要,因為它們可以識別自體抗體。各種自體免疫疾病(包括紅斑性狼瘡、多發性硬化症和類風濕性關節炎)的發生率不斷上升,推動了對免疫螢光檢測的需求。根據美國疾病管制與預防中心2024年 5月發布的估計,美國約有204,000 人患有系統性紅斑狼瘡(SLE)。早期檢測生物標記可能實現更安全的治療,減少副作用,並根據患者獨特的臨床和免疫特徵更有效地使用藥物。這確保了衛生服務和資源的合理利用和成本效益。
此外,領先的市場參與者和研究機構加強提高先進技術和新儀器的可用性,預計也將為市場提供有利的成長機會。成像系統和螢光染料的創新以及診斷系統的自動化提高了間接抗體螢光測定的特異性和敏感性。
本報告對全球免疫螢光測定市場進行調查分析,包括市場規模和預測、市場動態和主要參與者。
Global immunofluorescence assays market is projected to witness a CAGR of 6.39% during the forecast period 2025-2032, growing from USD 3.93 billion in 2024 to USD 6.44 billion in 2032. The growth of the market is supported by the rapid expansion of the biotechnology industry, the increasing burden on the healthcare sector, and rising investments in research and development activities.
Additionally, emerging applications of immunofluorescence assays in a wide range of domains bolstered the market's demand. Immunofluorescence assays can be deployed on tissues or cells to determine the presence or absence of various biological compounds such as proteins and carbohydrates. The technique is also utilized in molecular biology for visualization of cytoskeletons. Such applications significantly support the market's growth in different regions across the globe.
The growing threat of autoimmune diseases is one of the key global immunofluorescence assays market trends. The immunochemical technique allows the localization and detection of a wide range of antigens in various tissue types for cell preparation. Immunofluorescence assays are essential for diagnosing autoimmune diseases as they are able to recognize the autoantibodies. The rising incidences of different autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis, are propelling the requirement for immunofluorescence assays. As per the estimates published by the Centers for Disease Control and Prevention in May 2024, approximately 204,000 individuals in the United States are suffering from systemic lupus erythematosus (SLE). Early detection of biomarkers can allow the delivery of better and safer treatments with limited side effects along with the efficient utilization of drugs as they are tailored to the unique clinical and immunological features of the patients. Thus, ensuring the judicious usage of healthcare services and resources and cost efficiency.
The growing efforts of leading market players and research organizations to bolster the availability of sophisticated technologies and novel instruments are also expected to provide lucrative growth opportunities to the market. Innovations in imaging systems and fluorescent dyes coupled with automation of diagnostic systems are increasing the specificity and sensitivity of indirect fluorescent antibody techniques.
Increasing Prevalence of Chronic Diseases Boosts Market Demand
The growing threat of chronic diseases and disorders is one of the major drivers of the immunofluorescence assay market. The data published by the World Health Federation in May 2023 stated that the deaths from cardiovascular disease (CVD) have surged by 60% since 1990. The data further mentioned that CVD is a leading cause of death worldwide, with four in five CVD deaths occurring in low- and middle-income countries (LMICs).
Immunofluorescence assays play a crucial role in diagnosing and detecting a wide range of infectious, autoimmune, and chronic diseases. In cancer diagnostics, immunofluorescence assays allow the detection of tumor-specific antigens in a time-efficient manner, enabling early diagnosis and guiding healthcare professionals through personalized treatment approaches. Additionally, the growing threat of infectious diseases, including HIV and tuberculosis, is also bolstering the requirement for immunofluorescence assays for accurate and rapid pathogen detection. They also allow the identification of various drug-resistant and emerging disease strains. As the threat of such conditions rises, the demand for technological solutions that provide accurate results and timely diagnosis is increasing, as early detection and intervention are essential for effectively treating and managing various chronic conditions.
Rising Research Activities Support Market Expansion
Increasing investments in biomedical research, along with increasing studies for evaluating molecular and cellular mechanisms, validating therapeutic targets, and comprehending disease pathways, are propelling the market's expansion. An increasing number of clinical trials also support the market's expansion. For instance, Dartmouth Hitchcock Medical Center is conducting an observational study to evaluate the association between bone and tissue perfusion in efforts to develop indocyanine green fluorescence imaging as a diagnostic solution for quantitively guiding operative debridement. The study population includes patients with open fractures, and the secondary outcome measure of the study includes surgical site infection. The study is expected to conclude in January 2025. Moreover, the rising investments by different government organizations and research institutions to strengthen their country's biomedical research sector are also positively influencing the expansion of the immunofluorescence assay market. The rising emphasis on biomedical research can be attributed to evolving healthcare requirements, increasing global health challenges, and rising awareness among the general population. The histochemical staining technique is utilized to demonstrate the absence or presence of antibodies that are bound to antigens present in circulating body fluids or tissues. Thus, this will bolster the demand for immunofluorescence assays across research and academic institutions and positively influence the growth of the immunofluorescence assays market.
Pharmaceutical and Biotechnology Companies Account for Significant Share of the Market
The growing burden of different diseases, coupled with increasing investments in research and development activities in pharmaceutical and biotechnology industries to support the development of novel therapies and advanced diagnostic solutions, is propelling the growth of the global immunofluorescence assay market. Biotechnology and pharmaceutical companies deploy immunofluorescence assays in different drug discovery processes as well as for developing various diagnostic solutions. They are also widely used for validating and identifying therapeutic targets, monitoring biomarkers' expression, and assessing drug efficacy. Thus, making them crucial for developing immunological and oncological drugs, among others. The rising investments in research and development activities also provide lucrative growth opportunities for the market. As per the European Federation of Pharmaceutical Industries and Associations (EFPIA), approximately USD 52,079 million was invested in research and development by the pharmaceutical industry in Europe in 2023. Moreover, the increasing emphasis on personalized medicines is driving the adoption of advanced immunofluorescence assays by both pharmaceutical and biotechnology companies to enable the identification of patient-specific biomarkers to support the development of targeted treatments and improve clinical outcomes.
North America Holds Major Market Share
The presence of advanced technologies, increasing investments towards enhancing the healthcare sector, and the strong presence of leading research institutions and market players are some of the major factors supporting the growth of the North American immunofluorescence assay market. The increasing efforts of various government agencies in the region to boost awareness about various infectious diseases and curb their spreading is another major factor augmenting the requirement for immunofluorescence assays in the region. Additionally, the prevalence of chronic diseases such as cancer in countries such as the United States is also augmenting the market's demand. As per the estimates of the American Cancer Society, around 2,001,140 new cases of cancer were reported in the United States in 2024. Immunofluorescence provides valuable prognostic information by identifying cancer cells and showing where certain proteins are localized and expressed in the cancer cells along with other nonbiological and biological substances. Furthermore, the rising investments towards research activities and provision of funding opportunities by the governments in the region to foster research and innovation in biological and pharmaceutical domains are also expected to influence the market's expansion in North America positively.
Future Market Scenario (2025-2032F)
As per the global immunofluorescence assays market analysis, the market is expected to observe significant growth over the forecast period due to the growing burden of chronic and infectious diseases, increasing investments in the healthcare industry, and technological advancements. According to the estimates of WHO, approximately 35 million new cases of cancer are expected to be diagnosed in 2050. Technological advancements, including the integration of artificial intelligence with immunofluorescence imaging along with the increasing efforts to boost the development of automated platforms, are also expected to play a crucial role in shaping the market.
Additionally, the continuous efforts of the key players of the market to expand their product portfolios, coupled with their increasing focus on research and development, is expected to bolster the availability of user-friendly and economically efficient solutions in the coming years, increasing the accessibility of advanced diagnostic tools and supporting the market's expansion. Furthermore, the increasing efforts of various governments to improve their disease surveillance capabilities and strengthen their research sector is also expected to propel the demand for the immunofluorescence assays market.
Key Players Landscape and Outlook
The growth of the market is bolstered by increasing investments by leading pharmaceutical and biotechnology companies towards collaborations and partnerships to expand their global presence and ensure the availability of novel products and technologies. For instance, in January 2023, Akoya Biosciences, Inc. and Agilent Technologies, Inc. announced a partnership for developing multiplex-immunohistochemistry diagnostic solutions for analyzing tissues and commercializing workflow solutions for multiplex assays. By combining Akoya's imaging platform, PhenoImager HT, and Agilent's autostaining instrument, Dako Omnis, for immunofluorescent assays and multiplex chromogenic immunohistochemistry, the companies created a singular end-to-end commercial workflow that includes imaging, analysis, and staining. These assay solutions are allowing medical professionals and researchers to translate their discoveries into clinical solutions.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.